Market Overview

Alexion Spikes As Company Hires Goldman Sachs (ALXN)

Alexion Spikes As Company Hires Goldman Sachs ALXN
Related ALXN
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Alexion Announces Study Presented at ASN 2015 Supports Effectiveness of Soliris in Preventing TMA Events in Patients with aHUS

Shares of Alexion (NASDAQ: ALXN) spiked higher when Bloomberg reported that the pharmaceutical company will be working with Goldman Sachs (NYSE: GS) on a potential takeover by Roche (OTC: RHHBY).

Shares of Alexion jumped as high as $120.48, or 10.2 percent on the news. More than 2.5 million shares have already been traded, compared to the average of 2.03 million.

A previous offer from Roche was rejected, but Alexion will be working with Goldman Sachs in the case that Roche raises their offer to a level the pharmaceutical company finds appealing.

Bloomberg reported that Roche is interested in both the company’s blood medication and pipeline.

Analysts will likely review the company in the near future.

Posted-In: Alexion Goldman Sachs Pharmaceutical RocheNews Offerings Hot Best of Benzinga


Related Articles (ALXN + GS)

Get Benzinga's Newsletters